Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.61 |
| ▸ | CA2 | P00918 | 5/20 | 0.61 |
| ▸ | CA9 | Q16790 | 5/20 | 0.61 |
| ▸ | CA12 | O43570 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 2/20 | 0.41 |
| ▸ | CA5A | P35218 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10494691 | 0.85 | CA12 (0.46) | CA1CA2CA9CA12ALDH1A1 | |
| SCHEMBL3532040 | 0.84 | CA2 (0.56) | CA1CA2CA9CA12ALDH1A1 | |
| SCHEMBL6288936 | 0.81 | ALDH1A1 (0.46) | CA1ALDH1A1HPGDGAA | |
| SCHEMBL17327582 | 0.81 | IKBKB (0.44) | CA1CA2CA9CA12ALDH1A1 | |
| SCHEMBL634317 | 0.81 | ALDH1A1 (0.66) | CA1CA2CA9CA12ALDH1A1 | |
| SCHEMBL8890664 | 0.81 | ALDH1A1 (0.46) | CA1CA2CA9CA12ALDH1A1 | |
| SCHEMBL2990886 | 0.80 | CA1 (0.46) | CA1CA2CA9CA12ALDH1A1 | |
| SCHEMBL14039493 | 0.79 | ALDH1A1 (0.44) | CA1CA2CA9CA12ALDH1A1 | |
| SCHEMBL17029673 | 0.79 | HPGD (0.44) | CA1CA2CA9CA12ALDH1A1 | |
| SCHEMBL19708884 | 0.79 | CYP19A1 (0.50) | CA1CA2CA9CA12ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2137164-B1 | INHIBITORS OF PROTEIN KINASES | ASTRAZENECA AB (SE) | 2015-08-26 | — | — | EP | disclosed |
| EP-2137164-B1 | INHIBITORS OF PROTEIN KINASES | ASTRAZENECA AB (SE) | 2015-08-26 | — | — | EP | disclosed |
| US-8389521-B2 | Inhibitors of protein kinases | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-03-05 | — | — | US | disclosed |
| US-8389521-B2 | Inhibitors of protein kinases | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-03-05 | — | — | US | disclosed |
| US-8389521-B2 | Inhibitors of protein kinases | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-03-05 | — | — | US | disclosed |
| US-20100184780-A1 | INHIBITORS OF PROTEIN KINASES | ASTRAZENECA AB (SE) | 2010-07-22 | — | — | US | disclosed |
| US-20100184780-A1 | INHIBITORS OF PROTEIN KINASES | ASTRAZENECA AB (SE) | 2010-07-22 | — | — | US | disclosed |
| US-20100184780-A1 | INHIBITORS OF PROTEIN KINASES | ASTRAZENECA AB (SE) | 2010-07-22 | — | — | US | disclosed |
| EP-2137164-A1 | INHIBITORS OF PROTEIN KINASES | Ingenium Pharmaceuticals GmbH (DE) | 2009-12-30 | — | — | EP | disclosed |
| US-20080275063-A1 | C-{4-[6-(2-Ethoxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-N-propyl-methanesulfonamide; antiinflammatories, antiproliferatives, analgesics; cardiovascular disorders, neurodegenerative diseases; immunotherapy | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | US | disclosed |
| US-20080275063-A1 | C-{4-[6-(2-Ethoxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-N-propyl-methanesulfonamide; antiinflammatories, antiproliferatives, analgesics; cardiovascular disorders, neurodegenerative diseases; immunotherapy | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | US | disclosed |
| US-20080275063-A1 | C-{4-[6-(2-Ethoxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-N-propyl-methanesulfonamide; antiinflammatories, antiproliferatives, analgesics; cardiovascular disorders, neurodegenerative diseases; immunotherapy | ASTRAZENECA AB (SE) | 2008-11-06 | — | — | US | disclosed |
| WO-2008129069-A1 | INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008129069-A1 | INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184780-A1 | INHIBITORS OF PROTEIN KINASES | CDK5, CDK5R1, CDK1 | CA1 4746/4885CA2 3964/4885CA9 4833/4885 |
| US-20080275063-A1 | C-{4-[6-(2-Ethoxy-phenyl)-pyrimidin-4-ylamino]-phenyl}-N-propyl-methanesulfonamide; antiinflammatories, antiproliferatives, analgesics; cardiovascular disorders, neurodegenerative diseases; immunotherapy | CDK5, CDK5R1, CDK4 | CA1 4103/4885CA2 3085/4885CA9 4031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.